These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 1971512)

  • 21. [Association between uptake to lymphocytes from schizophrenic patients and therapeutic efficacy].
    Shimogawa S; Kaku H; Yoshimoto S; Nakane Y
    Yakubutsu Seishin Kodo; 1986 Jun; 6(2):239-46. PubMed ID: 2877529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and dopamine receptors binding affinity of 2-(3-fluoro-4-hydroxyphenyl)ethylamine and its N-alkyl derivatives.
    Cardellini M; Cingolani GM; Claudi F; Perlini V; Balduini W; Cattabeni F
    Farmaco Sci; 1988 Jan; 43(1):49-59. PubMed ID: 2899520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine-sensitive adenylate cyclase and dopamine/neuroleptic receptor binding: effect of neuroleptic drugs.
    Marshall AM; Mishra RK
    Adv Biochem Psychopharmacol; 1980; 24():153-7. PubMed ID: 6105772
    [No Abstract]   [Full Text] [Related]  

  • 24. Binding of 3H-spiperone to human peripheral lymphocytes: absence of stereospecific high-affinity binding.
    Feenstra A; Coggiano MA; Wyatt RJ
    Psychiatry Res; 1989 Dec; 30(3):259-64. PubMed ID: 2482515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abnormal glucocorticoid dependent increase of spiperone binding sites on lymphocytes from schizophrenics in vitro.
    Halbach M; Henning U
    Pharmacopsychiatry; 1989 Sep; 22(5):169-73. PubMed ID: 2813506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The sequestration of [3H]spiperone by lymphocytes in schizophrenics and their first-degree relatives: a limited vulnerability marker?
    Griffiths RS; Chung-a-on KO; Griffiths KD; Payne JW; Davies JI
    J Psychiatr Res; 1992 Jan; 26(1):77-84. PubMed ID: 1560411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3H-spiperone binding to lymphocytes in neuroleptic-naive-schizophrenia and the effect of neuroleptic treatment.
    Laufer N; Spivak B; Holdengreber V; Zipser J; Kosower N; Ragolsky M; Weizman A
    Clin Neuropharmacol; 1999; 22(2):110-4. PubMed ID: 10202608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methodology of 3H-spiperone binding to lymphocytes.
    Bondy B; Ackenheil M; Engel RR
    J Psychiatr Res; 1990; 24(1):83-92. PubMed ID: 1694898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High affinity 3H-spiperone binding to lymphocytes: reality of artefact?
    Bondy B; Ackenheil M
    Pharmacopsychiatry; 1991 Jan; 24(1):35-8. PubMed ID: 2011621
    [No Abstract]   [Full Text] [Related]  

  • 30. 3H-spiperone binding sites in lymphocytes as possible vulnerability marker in schizophrenia.
    Bondy B; Ackenheil M
    J Psychiatr Res; 1987; 21(4):521-9. PubMed ID: 3481637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Purification and properties of brain neuroleptic-binding proteins.
    Sartania NA; Abutidze KD; Mikeladze DG
    J Protein Chem; 1989 Jun; 8(3):339-40. PubMed ID: 2571344
    [No Abstract]   [Full Text] [Related]  

  • 32. Solubilized dopamine/neuroleptic receptors (D2-type).
    Madras BK; Davis A; Chan B; Seeman P
    Prog Neuropsychopharmacol; 1981; 5(5-6):543-8. PubMed ID: 6122229
    [No Abstract]   [Full Text] [Related]  

  • 33. Dopamine and migraine.
    Barbanti P; Fabbrini G; Cerbo R
    Neurology; 1998 Sep; 51(3):925. PubMed ID: 9748079
    [No Abstract]   [Full Text] [Related]  

  • 34. Interaction of [3H]spiperone with rat striatal dopamine D-2 receptors: kinetic evidence for antagonist-induced formation of ternary complex.
    Chatterjee TK; Scott CE; Vazquez DM; Bhatnagar RK
    Mol Pharmacol; 1988 Apr; 33(4):402-13. PubMed ID: 3357484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-affinity binding sites for neuroleptic drugs in human peripheral blood lymphocytes and their relation to dopamine receptors. A long-standing controversy.
    Vile JM; Strange PG
    Biochem Pharmacol; 1995 Mar; 49(6):747-53. PubMed ID: 7702632
    [No Abstract]   [Full Text] [Related]  

  • 36. Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranes.
    Hamblin MW; Creese I
    Mol Pharmacol; 1982 Jan; 21(1):44-51. PubMed ID: 6127621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormal neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The affinity of aromatic fluoride derivatives of phenothiazine neuroleptics to spiroperidol binding sites of dopamine receptors by the radioligand technic in vitro].
    Oelssner W; Peinhardt G; Büge A
    Pharmazie; 1985 May; 40(5):341-2. PubMed ID: 2863832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Kinetic characteristics of neuroleptic binding sites on human lymphocytes].
    Izumrudova II; Zaĭtsev SV; Koshkin AA; Porodenko NV; Varfolomeev SD
    Bioorg Khim; 1990 Feb; 16(2):272-4. PubMed ID: 1971512
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.